Medical Communications

NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …

After leasing the property for 25 years, Regeneron has agreed to take ownership of its headquarters and buy the Landmark …

Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable drugs due to “the presence …

Takeda UK has appointed Peter Wheatley Price to the role of market access director, where he will also sit on …

Inside this issue…

In response to a number of recent criticisms over pricing including president Trump’s message that pharma companies are “getting away …

The potential solutions offered by ‘big data’ seems to offer a vision of the future but potential solutions aren’t enough …

CEPI, the Coalition for Epidemic Preparedness Innovations, have launched the beginning of its fundraising initiative – with the aim of …

Pharmaceutical firms in India are not allowed to offer any kind of reimbursement for privileging certain treatment over others, this …

Researchers from Seoul National University Hospital have announced that it has developed a microchip that has been designed to replicate …

According to new data from intelligence provider GBI Research, the flu vaccines market in the Asia-Pacific (APAC) region is set …

A new study has estimated that one in four men could avoid unnecessary invasive biopsies to detect prostate cancer – …

Johnson & Johnson’s Imbruvica (ibrutinib) has scored its fifth indication approval in the US for the treatment of Marginal Zone …

It’s Friday, and there have been some big revelations for the pharma industry this week. Brexit, the ever-present hot topic …

Since their introduction in the UK in 2000, R&D tax credits have provided a significant boost to pharmaceutical and biotech …